Orange Book product · Generic (ANDA)
DESVENLAFAXINE SUCCINATE
DESVENLAFAXINE SUCCINATE
At a glance
Jan 15, 2025
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jan 15, 2025
1 yr 5 mo ago
Today
Pharmaceutical detail
Active ingredient
DESVENLAFAXINE SUCCINATE
Strength
EQ 50MG BASE
Dosage form
TABLET, EXTENDED RELEASE
Route
ORAL
TE code
AB
Application
ANDA 211427
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of DESVENLAFAXINE SUCCINATE
- 2014PRISTIQBrand (NDA)
NDA 021992 · PF PRISM CV
- 2026DESVENLAFAXINE SUCCINATEGeneric (ANDA)
ANDA 220460 · YICHANG HUMANWELL
- 2023DESVENLAFAXINE SUCCINATEGeneric (ANDA)
ANDA 204028 · RUBICON RESEARCH
- 2022DESVENLAFAXINE SUCCINATEGeneric (ANDA)
ANDA 204020 · ZYDUS PHARMS
- 2022DESVENLAFAXINE SUCCINATEGeneric (ANDA)
ANDA 204172 · LUPIN
- 2020DESVENLAFAXINE SUCCINATEGeneric (ANDA)
ANDA 210014 · YICHANG HUMANWELL
- 2019DESVENLAFAXINE SUCCINATEGeneric (ANDA)
ANDA 204805 · PLATINUM
- 2018DESVENLAFAXINE SUCCINATEGeneric (ANDA)
ANDA 204003 · ALEMBIC
- 2016DESVENLAFAXINE SUCCINATEGeneric (ANDA)
ANDA 204065 · ACTAVIS LABS FL
- 2016DESVENLAFAXINE SUCCINATEGeneric (ANDA)
ANDA 204083 · HIKMA
- 2015DESVENLAFAXINE SUCCINATEGeneric (ANDA)
ANDA 204095 · PHARMOBEDIENT
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
